Q2 2026 Recap: Nephrology News & Updates

The second quarter of 2026 brought continued momentum across nephrology, from landmark regulatory decisions and pivotal phase 3 trial results to advances in precision medicine and evolving approaches to chronic kidney disease (CKD) management. The quarter featured the first US Food and Drug Administration (FDA)-approved therapy for focal segmental glomerulosclerosis (FSGS), encouraging long-term data in IgA nephropathy (IgAN), and growing emphasis on earlier intervention and individualized care.